葡萄京娱乐场网上平台网站_入口

葡萄京娱乐场网上平台网站

News

To standardize management, management to promote efficiency, efficiency to promote innovation,
innovation and innovation to innovation and development.
Good news! Shandong Xinchuang biology won the 8th China Innovation and Entrepren

Scientific and technological innovation has made great achievements. On October 14, the final of the 8th China Innovation and entrepreneurship competition in biomedical industry, as the first national competition, ushered in the final peak battle in Guangzhou.
The contestants who are on the stage of today's final are the outstanding ones in Entrepreneurship and innovation from 30287 enterprises. Among them, nearly 3700 enterprises in the biomedical industry signed up for the competition, and 233 enterprises finally entered the finals of the biomedical industry after fierce competition and layer by layer selection in national local competitions. They started the local competition in June and spent several months "fighting", and finally entered the "highest stage" in the golden autumn. They are not only the "pacesetters" in the "trend" of mass innovation and entrepreneurship, but also the "fresh force" of the rise of China's biomedical innovation and entrepreneurship. Finally, singularity Pharmaceutical Technology (Guangzhou) Co., Ltd. of Guangzhou high tech Zone won the first prize of the start-up group, and Deqi (Zhejiang) Pharmaceutical Technology Co., Ltd. won the first prize of growth group. In addition, there are 22 "excellent enterprises" in the start-up group and 77 "excellent enterprises" in the growth enterprise group.
The five-day finals of the biomedical industry are rich and colorful. More than 1000 spectators, including government leaders, venture capital experts, entrepreneurship and innovation elites, students, media reporters and notaries, all attended the final, witnessing the wonderful "ultimate national war".
Shandong Xinchuang Biotechnology Co., Ltd. (hereinafter referred to as "Shandong Xinchuang biology") participated in the project of "new oncolytic bacteria class 1 new drug and its key anti-tumor technology combined with immunotherapy". After a fierce competition of primary selection, evaluation, roadshow and defense, Shandong Xinchuang Biotechnology Co., Ltd. relies on its leading scientific research and innovation ability, strong R & D team, abundant scientific research achievements and innovative business model And many other advantages, from the new sharp group of 61 on-the-spot promotion of participating enterprises, won the high recognition and score of the judges, and successfully won the first place in the Eighth China Innovation and Entrepreneurship Competition (Shandong competition area), and was shortlisted in the finals. After all-out efforts and careful polishing in the finals in October, the competition showed the innovative and entrepreneurial demeanor of struggling and vigorous Bo's corporate image finally stood out among many participating enterprises and won the excellent enterprise award of growth group. Only two enterprise projects in the province won the award. In the next step, the company and the team will actively promote the registration, application and clinical trials of class 1 Bacterial oncolytic drugs, striving to become the first bacterial oncolytic drug in China and even in the world, and benefit mankind!


Copyright © 2020 Shandong Xinchuang Biotechnology Co., Ltd. All Rights Reserved
Baidu
sogou